Johnson & Johnson (JNJ) Financials

$154.60 -0.40 (-0.26%)

Closing price 05/6/2025 03:59 PM Eastern

Extended Trading

$156.02 +1.42 (+0.92%)

As of 05/6/2025 08:00 PM Eastern

Annual Income Statements for Johnson & Johnson

This table shows Johnson & Johnson's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/3/2016	1/1/2017	12/31/2017	12/30/2018	12/29/2019	1/3/2021	1/2/2022	1/1/2023	12/31/2023	12/29/2024
Net Income / (Loss) Attributable to Common Shareholders	15,409	16,540	1,300	15,297	15,119	14,714	20,878	17,941	35,153	14,066
Consolidated Net Income / (Loss)	15,409	16,540	1,300	15,297	15,119	14,714	20,878	17,941	35,153	14,066
Net Income / (Loss) Continuing Operations	15,409	16,540	1,300	15,297	15,119	14,714	17,801	16,370	13,326	14,066
Total Pre-Tax Income	19,196	19,803	17,673	17,999	17,328	16,497	19,178	19,359	15,062	16,687
Total Operating Income	17,556	20,371	18,180	19,798	19,814	19,486	19,834	19,955	21,207	20,804
Total Gross Profit	48,538	50,101	51,011	54,490	54,503	54,157	55,338	55,394	58,606	61,350
Total Revenue	70,074	71,890	76,450	81,581	82,059	82,584	78,740	79,990	85,159	88,821
Operating Revenue	70,074	71,890	76,450	81,581	82,059	82,584	78,740	79,990	85,159	88,821
Total Cost of Revenue	21,536	21,789	25,439	27,091	27,556	28,427	23,402	24,596	26,553	27,471
Operating Cost of Revenue	21,536	21,789	25,439	27,091	27,556	28,427	23,402	24,596	26,553	27,471
Total Operating Expenses	30,982	29,730	32,831	34,692	34,689	34,671	35,504	35,439	37,399	40,546
Selling, General & Admin Expense	21,203	20,067	21,520	22,540	22,178	22,084	20,118	20,246	21,512	22,869
Research & Development Expense	9,270	9,172	11,002	11,901	12,245	12,340	15,177	14,918	15,398	17,443
Restructuring Charge	509	491	309	251	266	247	209	275	489	234
Total Other Income / (Expense), net	1,640	-568	-507	-1,799	-2,486	-2,989	-656	-596	-6,145	-4,117
Interest Expense	552	726	934	1,005	318	201	183	276	772	755
Interest & Investment Income	128	368	385	611	357	111	53	490	1,261	1,332
Other Income / (Expense), net	2,064	-210	42	-1,405	-2,525	-2,899	-526	-810	-6,634	-4,694
Income Tax Expense	3,787	3,263	16,373	2,702	2,209	1,783	1,377	2,989	1,736	2,621
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	3,077	1,571	21,827	0.00
Basic Earnings per Share	$5.56	$6.04	$0.48	$5.70	$5.72	$5.59	$7.93	$6.83	$13.88	$5.84
Weighted Average Basic Shares Outstanding	2.77B	2.74B	2.69B	2.68B	2.65B	2.63B	2.63B	2.63B	2.53B	2.41B
Diluted Earnings per Share	$5.48	$5.93	$0.47	$5.61	$5.63	$5.51	$7.81	$6.73	$13.72	$5.79
Weighted Average Diluted Shares Outstanding	2.81B	2.79B	2.75B	2.73B	2.68B	2.67B	2.67B	2.66B	2.56B	2.43B
Weighted Average Basic & Diluted Shares Outstanding	2.77B	2.74B	2.71B	2.68B	2.63B	2.63B	2.63B	2.60B	2.41B	2.41B
Cash Dividends to Common per Share	$2.95	$3.15	$3.32	$3.54	$3.75	$3.98	$4.19	$4.45	$4.70	$4.91

This table shows Johnson & Johnson's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	10/2/2022	1/1/2023	4/2/2023	7/2/2023	10/1/2023	12/31/2023	3/31/2024	6/30/2024	9/29/2024	12/29/2024	3/30/2025
Net Income / (Loss) Attributable to Common Shareholders	4,458	3,520	-68	5,144	26,028	4,049	3,255	4,686	2,694	3,431	10,999
Consolidated Net Income / (Loss)	4,458	3,520	-68	5,144	26,028	4,049	3,255	4,686	2,694	3,431	10,999
Net Income / (Loss) Continuing Operations	4,310	2,097	-491	5,376	4,309	4,132	3,255	4,686	2,694	3,431	10,999
Total Pre-Tax Income	5,172	2,485	-1,287	6,306	5,217	4,826	3,714	5,748	3,338	3,887	13,631
Total Operating Income	5,299	2,821	5,667	5,813	5,534	4,193	5,909	6,276	5,037	3,582	6,182
Total Gross Profit	13,824	9,641	14,207	15,057	14,745	14,597	14,872	15,578	15,508	15,392	14,536
Total Revenue	19,996	12,548	20,894	21,519	21,351	21,395	21,383	22,447	22,471	22,520	21,893
Operating Revenue	19,996	12,548	20,894	21,519	21,351	21,395	21,383	22,447	22,471	22,520	21,893
Total Cost of Revenue	6,172	2,907	6,687	6,462	6,606	6,798	6,511	6,869	6,963	7,128	7,357
Operating Cost of Revenue	6,172	2,907	6,687	6,462	6,606	6,798	6,511	6,869	6,963	7,128	7,357
Total Operating Expenses	8,525	6,820	8,540	9,244	9,211	10,404	8,963	9,302	10,471	11,810	8,354
Selling, General & Admin Expense	4,975	3,107	4,906	5,396	5,400	5,810	5,257	5,681	5,478	6,453	5,112
Marketing Expense	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Research & Development Expense	3,485	3,658	3,504	3,703	3,653	4,538	3,542	3,634	4,952	5,315	3,225
Restructuring Charge	65	55	130	145	158	56	164	-13	41	42	17
Total Other Income / (Expense), net	-127	-336	-6,954	493	-317	633	-2,195	-528	-1,699	305	7,449
Interest Expense	51	177	212	217	192	151	155	270	193	137	204
Interest & Investment Income	150	254	198	326	374	363	364	395	292	281	332
Other Income / (Expense), net	-226	-413	-6,940	384	-499	421	-2,404	-653	-1,798	161	7,321
Income Tax Expense	862	388	-796	930	908	694	459	1,062	644	456	2,632
Basic Earnings per Share	$1.70	$1.34	($0.03)	$1.98	$10.32	$1.61	$1.35	$1.95	$1.12	$1.42	$4.57
Weighted Average Basic Shares Outstanding	2.63B	2.63B	2.61B	2.60B	2.52B	2.53B	2.41B	2.41B	2.41B	2.41B	2.41B
Diluted Earnings per Share	$1.68	$1.32	($0.03)	$1.96	$10.21	$1.58	$1.34	$1.93	$1.11	$1.41	$4.54
Weighted Average Diluted Shares Outstanding	2.66B	2.66B	2.61B	2.63B	2.55B	2.56B	2.43B	2.42B	2.43B	2.43B	2.42B
Weighted Average Basic & Diluted Shares Outstanding	2.61B	2.60B	2.60B	2.60B	2.41B	2.41B	2.41B	2.41B	2.41B	2.41B	2.41B
Cash Dividends to Common per Share	$1.13	-	$1.13	$1.19	$1.19	-	$1.19	$1.24	$1.24	-	$1.24

This table details how cash moves in and out of Johnson & Johnson's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/3/2016	1/1/2017	12/31/2017	12/30/2018	12/29/2019	1/3/2021	1/2/2022	1/1/2023	12/31/2023	12/29/2024
Net Change in Cash & Equivalents	-791	5,240	-1,485	524	-802	-3,320	502	-360	7,732	2,246
Net Cash From Operating Activities	19,569	18,767	21,056	22,201	23,416	23,536	23,410	21,194	22,791	24,266
Net Cash From Continuing Operating Activities	19,569	18,767	21,056	22,201	23,416	23,536	23,410	21,194	22,791	24,266
Net Income / (Loss) Continuing Operations	15,409	16,540	1,300	15,297	15,119	14,714	20,878	17,941	35,153	14,066
Consolidated Net Income / (Loss)	15,409	16,540	1,300	15,297	15,119	14,714	20,878	17,941	35,153	14,066
Depreciation Expense	3,746	3,754	5,642	6,929	7,009	7,231	7,390	6,970	7,486	7,339
Non-Cash Adjustments To Reconcile Net Income	-945	587	467	988	-101	1,190	1,459	1,957	-18,161	3,207
Changes in Operating Assets and Liabilities, net	1,359	-2,114	13,647	-1,013	1,389	401	-6,317	-5,674	-1,687	-346
Net Cash From Investing Activities	-7,735	-4,761	-14,868	-3,167	-6,194	-20,825	-8,683	-12,371	878	-18,599
Net Cash From Continuing Investing Activities	-7,735	-4,761	-14,868	-3,167	-6,194	-20,825	-8,683	-12,371	878	-18,599
Purchase of Property, Plant & Equipment	-3,463	-3,226	-3,279	-3,670	-3,498	-3,347	-3,652	-4,009	-4,543	-4,424
Acquisitions	-954	-4,509	-35,151	-899	-5,810	-7,323	-60	-17,652	-470	-16,929
Purchase of Investments	-40,828	-33,950	-6,153	-5,626	-3,920	-21,089	-30,394	-32,384	-10,906	-1,726
Sale of Property, Plant & Equipment	3,464	1,267	1,832	3,203	3,265	305	711	543	358	675
Sale and/or Maturity of Investments	34,149	35,780	28,117	4,289	3,387	12,137	25,006	41,609	19,390	2,462
Other Investing Activities, net	-103	-123	-234	-464	382	-1,508	-294	-478	-2,951	1,343
Net Cash From Financing Activities	-11,136	-8,551	-7,673	-18,510	-18,015	-6,120	-14,047	-8,871	-15,825	-3,132
Net Cash From Continuing Financing Activities	-11,136	-8,551	-7,673	-18,510	-18,015	-6,120	-14,047	-8,871	-15,825	-3,132
Repayment of Debt	-1,169	-4,255	-3,295	-4,207	-2,448	-4,021	-2,878	-8,591	-16,746	-10,954
Repurchase of Common Equity	-5,290	-8,979	-6,358	-5,868	-6,746	-3,221	-3,456	-6,035	-5,054	-2,432
Payment of Dividends	-8,173	-8,621	-8,943	-9,494	-9,917	-10,481	-11,032	-11,682	-11,770	-11,823
Issuance of Debt	2,491	12,115	9,861	85	42	10,822	2,002	16,136	13,743	21,937
Issuance of Common Equity	-	-	-	-	-	-	0.00	0.00	4,241	0.00
Other Financing Activities, net	1,005	1,189	1,062	974	1,054	781	1,317	1,301	-239	140
Effect of Exchange Rate Changes	-1,489	-215	-	-	-9.00	89	-178	-312	-112	-289
Cash Interest Paid	1,132	1,358	1,826	2,012	1,920	1,745	1,931	1,915	3,602	3,901
Cash Income Taxes Paid	2,865	2,843	3,312	4,570	4,191	4,619	4,768	5,223	8,574	6,714

This table details how cash moves in and out of Johnson & Johnson's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	10/2/2022	1/1/2023	4/2/2023	7/2/2023	10/1/2023	12/31/2023	3/31/2024	6/30/2024	9/29/2024	12/29/2024	3/30/2025
Net Change in Cash & Equivalents	372	2,772	12,738	-5,682	-1,455	2,131	3,614	-595	-4,898	4,125	14,369
Net Cash From Operating Activities	6,284	5,350	3,257	4,182	7,489	7,863	3,657	5,633	7,993	6,983	4,174
Net Cash From Continuing Operating Activities	6,284	5,350	3,257	4,182	7,489	7,863	3,657	5,633	7,993	6,983	4,174
Net Income / (Loss) Continuing Operations	4,458	3,520	-68	5,144	26,028	4,049	3,255	4,686	2,694	3,431	10,999
Consolidated Net Income / (Loss)	4,458	3,520	-68	5,144	26,028	4,049	3,255	4,686	2,694	3,431	10,999
Depreciation Expense	1,685	1,772	1,880	1,934	1,829	1,843	1,815	1,782	1,846	1,896	1,772
Non-Cash Adjustments To Reconcile Net Income	310	472	-818	1,847	-20,326	1,136	487	312	1,534	874	255
Changes in Operating Assets and Liabilities, net	-169	-414	2,263	-4,743	-42	835	-1,900	-1,147	1,919	782	-8,852
Net Cash From Investing Activities	-1,701	-4,397	3,315	-3,776	2,541	-1,202	-464	-13,687	-3,128	-1,320	-297
Net Cash From Continuing Investing Activities	-1,701	-4,397	3,315	-3,776	2,541	-1,202	-464	-13,687	-3,128	-1,320	-297
Purchase of Property, Plant & Equipment	-952	-1,587	-863	-1,124	-967	-1,589	-807	-976	-1,029	-1,612	-795
Acquisitions	1.00	-17,130	0.00	-	-	-470	-1,811	-12,996	-338	-1,784	0.00
Purchase of Investments	-9,115	-1,221	-3,774	-5,914	-293	-925	-630	-554	-280	-262	-251
Sale of Property, Plant & Equipment	8.00	221	40	76	121	121	210	363	50	52	279
Sale and/or Maturity of Investments	8,690	15,285	7,766	4,111	3,910	3,603	979	727	466	290	218
Other Investing Activities, net	-333	35	146	-925	-230	-1,942	1,595	-251	-1,997	1,996	252
Net Cash From Financing Activities	-3,925	1,700	6,138	-5,991	-11,317	-4,655	546	7,544	-9,882	-1,340	10,422
Net Cash From Continuing Financing Activities	-3,925	1,700	6,138	-5,991	-11,317	-4,655	546	7,544	-9,882	-1,340	10,422
Repayment of Debt	-2,469	-1,778	-6,127	-8,038	180	-2,761	-798	-3,883	-4,515	-1,758	-2,831
Repurchase of Common Equity	-2,165	-1,320	-3,537	-381	-920	-216	-1,475	-136	-539	-282	-2,127
Payment of Dividends	-2,970	-2,954	-2,942	-3,092	-2,871	-2,865	-2,869	-2,985	-2,985	-2,984	-2,989
Issuance of Debt	2,727	9,036	18,768	1,127	-7,433	1,281	5,265	15,370	-1,991	3,293	17,922
Other Financing Activities, net	952	-1,284	-24	152	-273	-94	423	-822	148	391	447
Effect of Exchange Rate Changes	-286	119	28	-97	-168	125	-125	-85	119	-198	70

This table presents Johnson & Johnson's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/3/2016	1/1/2017	12/31/2017	12/30/2018	12/29/2019	1/3/2021	1/2/2022	1/1/2023	12/31/2023	12/29/2024
Total Assets	133,411	141,208	157,303	152,954	157,728	174,894	182,018	187,378	167,558	180,104
Total Current Assets	60,210	65,032	43,088	46,033	45,274	51,237	60,979	55,294	53,495	55,893
Cash & Equivalents	13,732	18,972	17,824	18,107	17,305	13,985	14,487	12,889	21,859	24,105
Short-Term Investments	24,644	22,935	472	1,580	1,982	11,200	17,121	9,392	1,068	417
Accounts Receivable	10,734	11,699	13,490	14,098	14,481	13,576	15,283	14,039	14,873	14,842
Inventories, net	8,053	8,144	8,765	8,599	9,020	9,344	10,387	10,268	11,181	12,444
Prepaid Expenses	3,047	3,282	2,537	2,699	2,392	3,132	3,701	2,876	4,514	4,085
Plant, Property, & Equipment, net	15,905	15,912	17,005	17,035	17,658	18,766	18,962	17,982	19,898	20,518
Total Noncurrent Assets	57,296	60,264	97,210	89,886	94,796	104,891	102,077	114,102	94,165	103,693
Goodwill	21,629	22,805	31,906	30,453	33,639	36,393	35,246	36,047	36,558	44,200
Intangible Assets	25,764	26,876	53,228	47,611	47,643	53,402	46,392	38,489	34,175	37,618
Noncurrent Deferred & Refundable Income Taxes	5,490	6,148	7,105	7,640	7,819	8,534	10,223	8,947	9,279	10,461
Other Noncurrent Operating Assets	4,413	4,435	4,971	4,182	5,695	6,562	10,216	9,212	14,153	11,414
Total Liabilities & Shareholders' Equity	133,411	141,208	157,303	152,954	157,728	174,894	182,018	187,378	167,558	180,104
Total Liabilities	62,261	70,790	97,143	93,202	98,257	111,616	107,995	110,574	98,784	108,614
Total Current Liabilities	27,747	26,287	30,537	31,230	35,964	42,493	45,226	55,802	46,282	50,321
Short-Term Debt	7,004	4,684	3,906	2,796	1,202	2,631	3,766	12,756	3,451	5,983
Accounts Payable	6,668	6,918	7,310	7,537	8,544	9,505	11,055	9,889	9,632	10,311
Accrued Expenses	10,851	11,038	14,514	16,981	20,598	25,481	25,707	24,298	26,213	26,129
Current Deferred & Payable Income Tax Liabilities	750	971	1,854	818	2,266	1,392	1,112	2,220	2,993	3,772
Current Employee Benefit Liabilities	2,474	2,676	2,953	3,098	3,354	3,484	3,586	3,049	3,993	4,126
Total Noncurrent Liabilities	34,514	44,503	66,606	61,972	62,293	69,123	62,769	54,772	52,502	58,293
Long-Term Debt	12,857	22,442	30,675	27,684	26,494	32,635	29,985	26,886	25,881	30,651
Noncurrent Deferred Revenue	-	0.00	8,472	8,242	7,444	6,559	5,713	4,306	2,881	390
Noncurrent Deferred & Payable Income Tax Liabilities	2,562	2,910	8,368	7,506	5,958	7,214	7,487	3,991	3,193	2,448
Noncurrent Employee Benefit Liabilities	8,854	9,615	10,074	9,951	10,663	10,771	8,898	6,542	7,149	7,255
Other Noncurrent Operating Liabilities	10,241	9,536	9,017	8,589	11,734	11,944	10,686	10,146	13,398	17,549
Commitments & Contingencies	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	71,150	70,418	60,160	59,752	59,471	63,278	74,023	76,804	68,774	71,490
Total Preferred & Common Equity	71,150	70,418	60,160	59,752	59,471	63,278	74,023	76,804	68,774	71,490
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	71,150	70,418	60,160	59,752	59,471	63,278	74,023	76,804	68,774	71,490
Common Stock	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120
Retained Earnings	103,879	110,551	101,793	106,216	110,659	113,890	123,060	128,345	153,843	155,791
Treasury Stock	-22,684	-28,352	-31,554	-34,362	-38,417	-38,490	-39,099	-41,694	-75,662	-75,680
Accumulated Other Comprehensive Income / (Loss)	-13,165	-14,901	-13,199	-15,222	-15,891	-15,242	-13,058	-12,967	-12,527	-11,741

This table presents Johnson & Johnson's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	10/2/2022	1/1/2023	4/2/2023	7/2/2023	10/1/2023	12/31/2023	3/31/2024	6/30/2024	9/29/2024	12/29/2024	3/30/2025
Total Assets	175,124	187,378	195,969	191,686	166,061	167,558	171,966	181,088	178,287	180,104	193,671
Total Current Assets	65,236	55,294	64,388	60,567	53,703	53,495	57,002	57,817	53,249	55,893	71,551
Cash & Equivalents	11,355	12,889	19,170	21,183	19,728	21,859	25,473	24,878	19,980	24,105	38,474
Short-Term Investments	22,724	9,392	5,443	7,322	3,783	1,068	745	597	317	417	307
Accounts Receivable	15,890	14,039	16,350	16,777	14,798	14,873	14,946	15,794	16,174	14,842	16,020
Inventories, net	11,675	10,268	12,809	12,888	11,198	11,181	11,383	12,169	12,603	12,444	12,659
Prepaid Expenses	3,592	2,876	2,921	2,397	4,196	4,514	4,455	4,379	4,175	4,085	4,091
Plant, Property, & Equipment, net	18,152	17,982	20,174	20,576	18,821	19,898	19,632	19,748	20,479	20,518	20,871
Plant, Property & Equipment, gross	46,681	-	50,367	51,218	45,626	-	47,585	48,035	49,274	-	49,884
Accumulated Depreciation	28,529	-	30,193	30,642	26,805	-	27,953	28,287	28,795	-	29,013
Total Noncurrent Assets	91,736	114,102	111,407	110,543	93,537	94,165	95,332	103,523	104,559	103,693	101,249
Goodwill	33,383	36,047	45,575	45,440	36,124	36,558	36,616	44,250	44,799	44,200	44,468
Intangible Assets	40,336	38,489	47,448	46,246	35,021	34,175	34,286	39,725	39,490	37,618	36,755
Noncurrent Deferred & Refundable Income Taxes	9,392	8,947	8,817	8,779	9,259	9,279	10,305	9,004	9,349	10,461	8,492
Other Noncurrent Operating Assets	8,625	9,212	9,567	10,078	13,133	14,153	14,125	10,544	10,921	11,414	11,534
Total Liabilities & Shareholders' Equity	175,124	187,378	195,969	191,686	166,061	167,558	171,966	181,088	178,287	180,104	193,671
Total Liabilities	100,525	110,574	125,100	115,277	94,833	98,784	101,946	109,550	108,129	108,614	115,562
Total Current Liabilities	45,543	55,802	60,373	54,170	44,370	46,282	48,725	53,933	51,759	50,321	56,903
Short-Term Debt	4,424	12,756	17,979	11,701	3,870	3,451	8,550	9,855	4,462	5,983	13,897
Accounts Payable	10,153	9,889	9,909	10,443	8,355	9,632	8,174	8,848	8,954	10,311	9,545
Accrued Expenses	25,974	24,298	25,988	26,277	25,909	26,213	26,505	28,078	29,889	26,129	26,693
Current Deferred & Payable Income Tax Liabilities	1,986	2,220	4,266	2,687	2,899	2,993	3,318	4,309	4,834	3,772	4,217
Current Employee Benefit Liabilities	3,006	3,049	2,231	3,062	3,337	3,993	2,178	2,843	3,620	4,126	2,551
Total Noncurrent Liabilities	54,982	54,772	64,727	61,107	50,463	52,502	53,221	55,617	56,370	58,293	58,659
Long-Term Debt	27,603	26,886	34,928	33,901	26,051	25,881	25,082	31,636	31,289	30,651	38,355
Noncurrent Deferred Revenue	4,162	4,306	4,296	2,536	2,540	2,881	2,881	341	354	390	395
Noncurrent Deferred & Payable Income Tax Liabilities	4,946	3,991	4,417	3,627	2,623	3,193	3,172	2,635	2,952	2,448	2,428
Noncurrent Employee Benefit Liabilities	8,353	6,542	6,665	6,461	5,687	7,149	7,019	6,919	6,852	7,255	7,046
Other Noncurrent Operating Liabilities	9,918	10,146	14,421	14,582	13,562	13,398	15,067	14,086	14,923	17,549	10,435
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	74,599	76,804	70,869	76,409	71,228	68,774	70,020	71,538	70,158	71,490	78,109
Total Preferred & Common Equity	74,599	76,804	70,869	75,149	71,228	68,774	70,020	71,538	70,158	71,490	78,109
Total Common Equity	74,599	76,804	70,869	75,149	71,228	68,774	70,020	71,538	70,158	71,490	78,109
Common Stock	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120
Retained Earnings	127,917	128,345	124,558	129,381	152,536	153,843	153,378	155,360	155,179	155,791	162,635
Accumulated Other Comprehensive Income / (Loss)	-15,292	-12,967	-12,626	-13,135	-8,780	-12,527	-10,768	-11,253	-12,522	-11,741	-11,740
Other Equity Adjustments	-	-	-44,183	-44,217	-75,648	-	-75,710	-75,689	-75,619	-	-75,906

This table displays calculated financial ratios and metrics derived from Johnson & Johnson's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/3/2016	1/1/2017	12/31/2017	12/30/2018	12/29/2019	1/3/2021	1/2/2022	1/1/2023	12/31/2023	12/29/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-5.73%	2.59%	6.34%	6.71%	0.59%	0.64%	-4.65%	1.59%	6.46%	4.30%
EBITDA Growth	-6.25%	2.35%	-0.21%	6.11%	-4.04%	-1.98%	12.09%	-2.18%	-15.53%	6.30%
EBIT Growth	-6.70%	2.76%	-9.62%	0.94%	-6.00%	-4.06%	16.40%	-0.84%	-23.88%	10.55%
NOPAT Growth	-15.30%	20.73%	-92.14%	1,158.21%	2.75%	0.53%	5.93%	-8.34%	11.19%	-6.54%
Net Income Growth	-5.60%	7.34%	-92.14%	1,076.69%	-1.16%	-2.68%	41.89%	-14.07%	95.94%	-59.99%
EPS Growth	-3.86%	8.21%	-92.07%	1,093.62%	0.36%	-2.13%	41.74%	-13.83%	103.86%	-57.80%
Operating Cash Flow Growth	4.59%	-4.10%	12.20%	5.44%	5.47%	0.51%	-0.54%	-9.47%	7.54%	6.47%
Free Cash Flow Firm Growth	-30.36%	-16.99%	-238.95%	221.60%	-19.34%	-38.17%	32.15%	25.75%	-13.34%	-46.40%
Invested Capital Growth	-5.03%	5.70%	37.40%	-8.96%	-2.60%	8.22%	3.83%	-3.61%	2.40%	11.20%
Revenue Q/Q Growth	-0.63%	0.41%	2.81%	0.24%	0.43%	2.14%	-13.89%	3.60%	11.59%	1.28%
EBITDA Q/Q Growth	4.86%	2.42%	-3.42%	1.17%	4.86%	-9.07%	-1.96%	4.20%	11.51%	-3.37%
EBIT Q/Q Growth	5.60%	2.77%	-8.34%	2.38%	6.44%	-13.10%	-2.21%	6.23%	17.84%	-5.13%
NOPAT Q/Q Growth	-7.01%	8.77%	-91.64%	937.45%	0.51%	-0.71%	-10.68%	3.89%	6.57%	-2.26%
Net Income Q/Q Growth	4.72%	3.76%	-91.79%	892.02%	6.84%	-13.38%	16.77%	-6.35%	1.53%	-4.21%
EPS Q/Q Growth	4.78%	4.22%	-91.84%	867.24%	7.24%	-13.36%	16.74%	-6.27%	1.93%	-2.85%
Operating Cash Flow Q/Q Growth	2.52%	9.12%	-2.54%	0.63%	0.66%	9.01%	-10.03%	-1.77%	12.39%	-3.50%
Free Cash Flow Firm Q/Q Growth	-15.64%	35.84%	-10.64%	31.38%	-21.82%	-23.50%	-16.87%	16.14%	35.87%	-8.57%
Invested Capital Q/Q Growth	-2.52%	-6.22%	-17.73%	-9.04%	-2.17%	2.80%	4.05%	1.20%	-3.17%	-2.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.27%	69.69%	66.72%	66.79%	66.42%	65.58%	70.28%	69.25%	68.82%	69.07%
EBITDA Margin	33.34%	33.27%	31.22%	31.04%	29.61%	28.84%	33.91%	32.65%	25.90%	26.40%
Operating Margin	25.05%	28.34%	23.78%	24.27%	24.15%	23.60%	25.19%	24.95%	24.90%	23.42%
EBIT Margin	28.00%	28.04%	23.84%	22.55%	21.07%	20.09%	24.52%	23.93%	17.11%	18.14%
Profit (Net Income) Margin	21.99%	23.01%	1.70%	18.75%	18.42%	17.82%	26.52%	22.43%	41.28%	15.84%
Tax Burden Percent	80.27%	83.52%	7.36%	84.99%	87.25%	89.19%	108.86%	92.68%	233.39%	84.29%
Interest Burden Percent	97.84%	98.22%	96.99%	97.86%	100.23%	99.46%	99.33%	101.12%	103.36%	103.58%
Effective Tax Rate	19.73%	16.48%	92.64%	15.01%	12.75%	10.81%	7.18%	15.44%	11.53%	15.71%
Return on Invested Capital (ROIC)	26.08%	31.43%	2.02%	23.04%	25.17%	24.63%	24.62%	22.56%	25.25%	22.09%
ROIC Less NNEP Spread (ROIC-NNEP)	18.07%	34.28%	-2.93%	11.34%	1.28%	-4.36%	65.01%	-149.26%	1,110.70%	-15.39%
Return on Net Nonoperating Assets (RNNOA)	-4.21%	-8.06%	-0.03%	2.47%	0.19%	-0.65%	5.79%	1.23%	23.04%	-2.03%
Return on Equity (ROE)	21.87%	23.37%	1.99%	25.51%	25.36%	23.97%	30.41%	23.79%	48.29%	20.06%
Cash Return on Invested Capital (CROIC)	31.24%	25.88%	-29.48%	32.42%	27.80%	16.73%	20.87%	26.23%	22.88%	11.48%
Operating Return on Assets (OROA)	14.88%	14.68%	12.21%	11.86%	11.13%	9.97%	10.82%	10.37%	8.21%	9.27%
Return on Assets (ROA)	11.68%	12.05%	0.87%	9.86%	9.73%	8.85%	11.70%	9.71%	19.81%	8.09%
Return on Common Equity (ROCE)	21.87%	23.37%	1.99%	25.51%	25.36%	23.97%	30.41%	23.79%	48.29%	20.06%
Return on Equity Simple (ROE_SIMPLE)	21.66%	23.49%	2.16%	25.60%	25.42%	23.25%	28.20%	23.36%	51.11%	19.68%
Net Operating Profit after Tax (NOPAT)	14,093	17,014	1,337	16,826	17,288	17,380	18,410	16,874	18,763	17,536
NOPAT Margin	20.11%	23.67%	1.75%	20.62%	21.07%	21.05%	23.38%	21.10%	22.03%	19.74%
Net Nonoperating Expense Percent (NNEP)	8.02%	-2.85%	4.96%	11.70%	23.89%	28.98%	-40.38%	171.82%	-1,085.45%	37.48%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	14.49%	19.13%	16.22%
Cost of Revenue to Revenue	30.73%	30.31%	33.28%	33.21%	33.58%	34.42%	29.72%	30.75%	31.18%	30.93%
SG&A Expenses to Revenue	30.26%	27.91%	28.15%	27.63%	27.03%	26.74%	25.55%	25.31%	25.26%	25.75%
R&D to Revenue	13.23%	12.76%	14.39%	14.59%	14.92%	14.94%	19.27%	18.65%	18.08%	19.64%
Operating Expenses to Revenue	44.21%	41.35%	42.94%	42.52%	42.27%	41.98%	45.09%	44.30%	43.92%	45.65%
Earnings before Interest and Taxes (EBIT)	19,620	20,161	18,222	18,393	17,289	16,587	19,308	19,145	14,573	16,110
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	23,366	23,915	23,864	25,322	24,298	23,818	26,698	26,115	22,059	23,449
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.17	3.63	5.22	4.91	5.70	5.95	5.66	5.66	5.32	4.89
Price to Tangible Book Value (P/TBV)	9.49	12.33	0.00	0.00	0.00	0.00	0.00	191.57	0.00	0.00
Price to Revenue (P/Rev)	3.22	3.56	4.11	3.60	4.13	4.56	5.33	5.43	4.29	3.93
Price to Earnings (P/E)	14.64	15.46	241.73	19.19	22.43	25.57	20.08	24.22	10.40	24.83
Dividend Yield	3.62%	3.35%	2.84%	3.23%	2.91%	2.78%	2.63%	2.68%	3.09%	3.39%
Earnings Yield	6.83%	6.47%	0.41%	5.21%	4.46%	3.91%	4.98%	4.13%	9.61%	4.03%
Enterprise Value to Invested Capital (EV/IC)	3.93	4.33	4.32	4.37	5.13	5.27	5.53	6.15	4.95	4.32
Enterprise Value to Revenue (EV/Rev)	2.95	3.35	4.32	3.73	4.24	4.68	5.35	5.65	4.37	4.07
Enterprise Value to EBITDA (EV/EBITDA)	8.86	10.08	13.85	12.02	14.30	16.22	15.79	17.30	16.87	15.41
Enterprise Value to EBIT (EV/EBIT)	10.55	11.95	18.14	16.54	20.10	23.29	21.83	23.60	25.54	22.43
Enterprise Value to NOPAT (EV/NOPAT)	14.69	14.16	247.16	18.09	20.10	22.23	22.89	26.78	19.83	20.61
Enterprise Value to Operating Cash Flow (EV/OCF)	10.58	12.84	15.70	13.71	14.84	16.41	18.00	21.32	16.33	14.89
Enterprise Value to Free Cash Flow (EV/FCFF)	12.26	17.20	0.00	12.85	18.20	32.72	27.01	23.03	21.89	39.65
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.28	0.39	0.57	0.51	0.47	0.56	0.46	0.52	0.43	0.51
Long-Term Debt to Equity	0.18	0.32	0.51	0.46	0.45	0.52	0.41	0.35	0.38	0.43
Financial Leverage	-0.23	-0.24	0.01	0.22	0.15	0.15	0.09	-0.01	0.02	0.13
Leverage Ratio	1.87	1.94	2.29	2.59	2.61	2.71	2.60	2.45	2.44	2.48
Compound Leverage Factor	1.83	1.91	2.22	2.53	2.61	2.70	2.58	2.48	2.52	2.57
Debt to Total Capital	21.82%	27.81%	36.50%	33.78%	31.77%	35.79%	31.32%	34.04%	29.90%	33.88%
Short-Term Debt to Total Capital	7.70%	4.80%	4.12%	3.10%	1.38%	2.67%	3.49%	10.95%	3.52%	5.53%
Long-Term Debt to Total Capital	14.13%	23.01%	32.38%	30.68%	30.39%	33.12%	27.82%	23.09%	26.38%	28.35%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	78.18%	72.19%	63.50%	66.22%	68.23%	64.21%	68.68%	65.96%	70.10%	66.12%
Debt to EBITDA	0.85	1.13	1.45	1.20	1.14	1.48	1.26	1.52	1.33	1.56
Net Debt to EBITDA	-0.79	-0.62	0.68	0.43	0.35	0.42	0.08	0.66	0.29	0.52
Long-Term Debt to EBITDA	0.55	0.94	1.29	1.09	1.09	1.37	1.12	1.03	1.17	1.31
Debt to NOPAT	1.41	1.59	25.86	1.81	1.60	2.03	1.83	2.35	1.56	2.09
Net Debt to NOPAT	-1.31	-0.87	12.18	0.64	0.49	0.58	0.12	1.03	0.34	0.69
Long-Term Debt to NOPAT	0.91	1.32	22.94	1.65	1.53	1.88	1.63	1.59	1.38	1.75
Altman Z-Score	4.57	4.57	3.81	3.91	4.01	3.78	4.16	4.08	4.35	3.97
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.17	2.47	1.41	1.47	1.26	1.21	1.35	0.99	1.16	1.11
Quick Ratio	1.77	2.04	1.04	1.08	0.94	0.91	1.04	0.65	0.82	0.78
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	16,881	14,012	-19,471	23,676	19,097	11,807	15,603	19,621	17,003	9,113
Operating Cash Flow to CapEx	0.00%	957.99%	1,455.15%	4,753.96%	10,049.79%	773.70%	795.99%	611.48%	544.59%	647.27%
Free Cash Flow to Firm to Interest Expense	30.58	19.30	-20.85	23.56	60.05	58.74	85.26	71.09	22.02	12.07
Operating Cash Flow to Interest Expense	35.45	25.85	22.54	22.09	73.64	117.09	127.92	76.79	29.52	32.14
Operating Cash Flow Less CapEx to Interest Expense	35.45	23.15	20.99	21.63	72.90	101.96	111.85	64.23	24.10	27.17
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.53	0.52	0.51	0.53	0.53	0.50	0.44	0.43	0.48	0.51
Accounts Receivable Turnover	6.45	6.41	6.07	5.91	5.74	5.89	5.46	5.46	5.89	5.98
Inventory Turnover	2.65	2.69	3.01	3.12	3.13	3.10	2.37	2.38	2.48	2.33
Fixed Asset Turnover	4.38	4.52	4.65	4.79	4.73	4.53	4.17	4.33	4.50	4.40
Accounts Payable Turnover	3.01	3.21	3.58	3.65	3.43	3.15	2.28	2.35	2.72	2.76
Days Sales Outstanding (DSO)	56.56	56.95	60.13	61.72	63.56	62.00	66.89	66.90	61.96	61.06
Days Inventory Outstanding (DIO)	137.60	135.66	121.31	116.97	116.69	117.90	153.87	153.26	147.42	156.95
Days Payable Outstanding (DPO)	121.19	113.79	102.07	100.02	106.50	115.87	160.34	155.40	134.17	132.49
Cash Conversion Cycle (CCC)	72.97	78.82	79.36	78.67	73.75	64.02	60.42	64.75	75.21	85.52
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	52,635	55,637	76,445	69,595	67,786	73,359	76,166	73,419	75,179	83,602
Invested Capital Turnover	1.30	1.33	1.16	1.12	1.19	1.17	1.05	1.07	1.15	1.12
Increase / (Decrease) in Invested Capital	-2,788	3,002	20,808	-6,850	-1,809	5,573	2,807	-2,747	1,760	8,423
Enterprise Value (EV)	207,028	240,973	330,529	304,303	347,556	386,341	421,449	451,852	372,143	361,338
Market Capitalization	225,543	255,754	314,244	293,510	339,147	376,260	419,306	434,491	365,738	349,226
Book Value per Share	$25.71	$25.88	$22.39	$22.28	$22.60	$24.04	$28.12	$29.38	$28.57	$29.69
Tangible Book Value per Share	$8.59	$7.62	($9.30)	($6.83)	($8.29)	($10.07)	($2.89)	$0.87	($0.81)	($4.29)
Total Capital	91,011	97,544	94,741	90,232	87,167	98,544	107,774	116,446	98,106	108,124
Total Debt	19,861	27,126	34,581	30,480	27,696	35,266	33,751	39,642	29,332	36,634
Total Long-Term Debt	12,857	22,442	30,675	27,684	26,494	32,635	29,985	26,886	25,881	30,651
Net Debt	-18,515	-14,781	16,285	10,793	8,409	10,081	2,143	17,361	6,405	12,112
Capital Expenditures (CapEx)	-1.00	1,959	1,447	467	233	3,042	2,941	3,466	4,185	3,749
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,091	1,522	-1,839	-2,088	-8,775	-13,810	-12,089	-10,033	-12,263	-12,967
Debt-free Net Working Capital (DFNWC)	39,467	43,429	16,457	17,599	10,512	11,375	19,519	12,248	10,664	11,555
Net Working Capital (NWC)	32,463	38,745	12,551	14,803	9,310	8,744	15,753	-508	7,213	5,572
Net Nonoperating Expense (NNE)	-1,316	474	37	1,529	2,169	2,666	-2,468	-1,067	-16,390	3,470
Net Nonoperating Obligations (NNO)	-18,515	-14,781	16,285	9,843	8,315	10,081	2,143	-3,385	6,405	12,112
Total Depreciation and Amortization (D&A)	3,746	3,754	5,642	6,929	7,009	7,231	7,390	6,970	7,486	7,339
Debt-free, Cash-free Net Working Capital to Revenue	1.56%	2.12%	-2.41%	-2.56%	-10.69%	-16.72%	-15.35%	-12.54%	-14.40%	-14.60%
Debt-free Net Working Capital to Revenue	56.32%	60.41%	21.53%	21.57%	12.81%	13.77%	24.79%	15.31%	12.52%	13.01%
Net Working Capital to Revenue	46.33%	53.89%	16.42%	18.15%	11.35%	10.59%	20.01%	-0.64%	8.47%	6.27%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$5.56	$6.04	$0.48	$0.00	$5.72	$5.59	$7.93	$6.83	$13.88	$5.84
Adjusted Weighted Average Basic Shares Outstanding	2.77B	2.74B	2.69B	0.00	2.65B	2.63B	2.63B	2.63B	2.53B	2.41B
Adjusted Diluted Earnings per Share	$5.48	$5.93	$0.47	$0.00	$5.63	$5.51	$7.81	$6.73	$13.72	$5.79
Adjusted Weighted Average Diluted Shares Outstanding	2.81B	2.79B	2.75B	0.00	2.68B	2.67B	2.67B	2.66B	2.56B	2.43B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.76B	2.71B	2.68B	0.00	2.63B	2.63B	2.63B	2.60B	2.41B	2.41B
Normalized Net Operating Profit after Tax (NOPAT)	14,501	17,425	12,942	17,039	17,520	17,600	18,604	17,107	19,195	17,734
Normalized NOPAT Margin	20.69%	24.24%	16.93%	20.89%	21.35%	21.31%	23.63%	21.39%	22.54%	19.97%
Pre Tax Income Margin	27.39%	27.55%	23.12%	22.06%	21.12%	19.98%	24.36%	24.20%	17.69%	18.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	35.54	27.77	19.51	18.30	54.37	82.52	105.51	69.37	18.88	21.34
NOPAT to Interest Expense	25.53	23.44	1.43	16.74	54.37	86.47	100.60	61.14	24.30	23.23
EBIT Less CapEx to Interest Expense	35.55	25.07	17.96	17.84	53.64	67.39	89.44	56.81	13.46	16.37
NOPAT Less CapEx to Interest Expense	25.53	20.74	-0.12	16.28	53.63	71.33	84.53	48.58	18.88	18.26
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	53.04%	52.12%	687.92%	62.06%	65.59%	71.23%	52.84%	65.11%	33.48%	84.05%
Augmented Payout Ratio	87.37%	106.41%	1,177.00%	100.42%	110.21%	93.12%	69.39%	98.75%	47.86%	101.34%

This table displays calculated financial ratios and metrics derived from Johnson & Johnson's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	10/2/2022	1/1/2023	4/2/2023	7/2/2023	10/1/2023	12/31/2023	3/31/2024	6/30/2024	9/29/2024	12/29/2024	3/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-14.32%	28.45%	-10.81%	-10.41%	6.78%	70.51%	2.34%	4.31%	5.25%	5.26%	2.39%
EBITDA Growth	19.19%	33.63%	-92.03%	7.58%	1.57%	54.47%	776.44%	-8.93%	-25.92%	-12.67%	187.12%
EBIT Growth	31.56%	87.39%	-121.76%	6.59%	-0.75%	91.61%	375.33%	-9.26%	-35.67%	-18.88%	285.25%
NOPAT Growth	-18.77%	33.47%	-21.43%	-1.23%	3.51%	50.81%	30.55%	3.24%	-11.06%	-11.93%	-3.68%
Net Income Growth	21.57%	-25.68%	-101.32%	6.86%	483.85%	15.03%	4,886.76%	-8.90%	-89.65%	-15.26%	237.91%
EPS Growth	22.63%	-25.42%	-101.55%	8.89%	507.74%	19.70%	4,566.67%	-1.53%	-89.13%	-10.76%	238.81%
Operating Cash Flow Growth	-24.20%	-6.66%	-18.15%	-25.07%	19.18%	46.97%	12.28%	34.70%	6.73%	-11.19%	14.14%
Free Cash Flow Firm Growth	40.92%	601.04%	-516.64%	-290.41%	-110.26%	-64.31%	291.51%	190.99%	-651.44%	-387.49%	-147.66%
Invested Capital Growth	-0.89%	-3.61%	18.07%	22.41%	7.02%	2.40%	-15.34%	-6.37%	10.27%	11.20%	18.27%
Revenue Q/Q Growth	-16.75%	-37.25%	66.51%	2.99%	-0.78%	0.21%	-0.06%	4.98%	0.11%	0.22%	-2.78%
EBITDA Q/Q Growth	-10.58%	-38.15%	-85.48%	1,239.54%	-15.58%	-5.93%	-17.61%	39.19%	-31.33%	10.89%	170.88%
EBIT Q/Q Growth	-12.75%	-52.53%	-152.87%	586.80%	-18.75%	-8.36%	-24.04%	60.43%	-42.40%	15.56%	260.75%
NOPAT Q/Q Growth	-11.99%	-46.09%	66.64%	24.93%	-7.77%	-21.46%	44.25%	-1.20%	-20.55%	-22.22%	57.77%
Net Income Q/Q Growth	-7.40%	-21.04%	-101.93%	7,664.71%	405.99%	-84.44%	-19.61%	43.96%	-42.51%	27.36%	220.58%
EPS Q/Q Growth	-6.67%	-21.43%	-102.27%	6,633.33%	420.92%	-84.53%	-15.19%	44.03%	-42.49%	27.03%	221.99%
Operating Cash Flow Q/Q Growth	12.60%	-14.86%	-39.12%	28.40%	79.08%	4.99%	-53.49%	54.03%	41.90%	-12.64%	-40.23%
Free Cash Flow Firm Q/Q Growth	-20.67%	1.18%	-295.65%	-21.25%	95.72%	451.81%	949.86%	-42.39%	-135.31%	-34.60%	-74.06%
Invested Capital Q/Q Growth	-5.03%	1.20%	24.58%	2.23%	-16.97%	-3.17%	3.00%	13.07%	-2.22%	-2.35%	9.54%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.13%	76.83%	68.00%	69.97%	69.06%	68.23%	69.55%	69.40%	69.01%	68.35%	66.40%
EBITDA Margin	33.80%	33.31%	2.91%	37.79%	32.15%	30.18%	24.88%	32.99%	22.63%	25.04%	69.77%
Operating Margin	26.50%	22.48%	27.12%	27.01%	25.92%	19.60%	27.63%	27.96%	22.42%	15.91%	28.24%
EBIT Margin	25.37%	19.19%	-6.09%	28.80%	23.58%	21.57%	16.39%	25.05%	14.41%	16.62%	61.68%
Profit (Net Income) Margin	22.29%	28.05%	-0.33%	23.90%	121.91%	18.93%	15.22%	20.88%	11.99%	15.24%	50.24%
Tax Burden Percent	86.19%	141.65%	5.28%	81.57%	498.91%	83.90%	87.64%	81.52%	80.71%	88.27%	80.69%
Interest Burden Percent	101.95%	103.20%	101.10%	101.76%	103.61%	104.59%	105.96%	102.22%	103.06%	103.85%	100.95%
Effective Tax Rate	16.67%	15.61%	0.00%	14.75%	17.40%	14.38%	12.36%	18.48%	19.29%	11.73%	19.31%
Return on Invested Capital (ROIC)	23.40%	20.29%	17.41%	20.32%	21.76%	19.23%	24.56%	21.80%	19.44%	15.71%	24.09%
ROIC Less NNEP Spread (ROIC-NNEP)	33.04%	-163.20%	-17.14%	22.52%	1,006.48%	49.63%	10.83%	19.20%	6.89%	18.62%	81.65%
Return on Net Nonoperating Assets (RNNOA)	0.20%	1.34%	-2.75%	2.52%	30.08%	1.03%	2.15%	4.30%	1.07%	2.46%	11.51%
Return on Equity (ROE)	23.60%	21.63%	14.66%	22.85%	51.83%	20.26%	26.72%	26.09%	20.50%	18.17%	35.60%
Cash Return on Invested Capital (CROIC)	23.18%	26.23%	4.10%	0.40%	16.67%	22.88%	38.23%	26.90%	12.21%	11.48%	3.71%
Operating Return on Assets (OROA)	11.06%	8.31%	-2.52%	11.69%	10.55%	10.35%	7.63%	11.64%	7.34%	8.49%	30.14%
Return on Assets (ROA)	9.72%	12.15%	-0.13%	9.70%	54.53%	9.08%	7.09%	9.70%	6.11%	7.78%	24.55%
Return on Common Equity (ROCE)	23.60%	21.63%	14.66%	22.66%	51.83%	20.26%	26.72%	25.87%	20.50%	18.17%	35.60%
Return on Equity Simple (ROE_SIMPLE)	25.68%	0.00%	17.95%	17.37%	48.61%	0.00%	54.95%	53.14%	20.93%	0.00%	27.92%
Net Operating Profit after Tax (NOPAT)	4,416	2,381	3,967	4,956	4,571	3,590	5,179	5,116	4,065	3,162	4,988
NOPAT Margin	22.08%	18.97%	18.99%	23.03%	21.41%	16.78%	24.22%	22.79%	18.09%	14.04%	22.79%
Net Nonoperating Expense Percent (NNEP)	-9.64%	183.49%	34.55%	-2.20%	-984.73%	-30.40%	13.73%	2.60%	12.54%	-2.91%	-57.56%
Return On Investment Capital (ROIC_SIMPLE)	-	2.04%	-	-	-	3.66%	-	-	-	2.92%	3.83%
Cost of Revenue to Revenue	30.87%	23.17%	32.00%	30.03%	30.94%	31.77%	30.45%	30.60%	30.99%	31.65%	33.60%
SG&A Expenses to Revenue	24.88%	24.76%	23.48%	25.08%	25.29%	27.16%	24.59%	25.31%	24.38%	28.65%	23.35%
R&D to Revenue	17.43%	29.15%	16.77%	17.21%	17.11%	21.21%	16.56%	16.19%	22.04%	23.60%	14.73%
Operating Expenses to Revenue	42.63%	54.35%	40.87%	42.96%	43.14%	48.63%	41.92%	41.44%	46.60%	52.44%	38.16%
Earnings before Interest and Taxes (EBIT)	5,073	2,408	-1,273	6,197	5,035	4,614	3,505	5,623	3,239	3,743	13,503
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	6,758	4,180	607	8,131	6,864	6,457	5,320	7,405	5,085	5,639	15,275
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.47	5.66	5.48	5.55	5.51	5.32	5.39	4.92	5.54	4.89	5.05
Price to Tangible Book Value (P/TBV)	463.37	191.57	0.00	0.00	4,727.39	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	5.28	5.43	5.02	5.56	5.14	4.29	4.41	4.06	4.43	3.93	4.41
Price to Earnings (P/E)	21.29	24.22	30.53	31.95	11.33	10.40	9.82	9.25	26.46	24.83	18.07
Dividend Yield	2.82%	2.68%	3.03%	2.85%	3.07%	3.09%	3.03%	3.29%	3.01%	3.39%	3.03%
Earnings Yield	4.70%	4.13%	3.28%	3.13%	8.82%	9.61%	10.19%	10.81%	3.78%	4.03%	5.53%
Enterprise Value to Invested Capital (EV/IC)	5.59	6.15	4.47	4.66	5.14	4.95	4.97	4.20	4.72	4.32	4.45
Enterprise Value to Revenue (EV/Rev)	5.25	5.65	5.28	5.81	5.23	4.37	4.50	4.25	4.61	4.07	4.56
Enterprise Value to EBITDA (EV/EBITDA)	16.19	17.30	21.41	22.13	20.16	16.87	14.39	14.12	16.65	15.41	12.20
Enterprise Value to EBIT (EV/EBIT)	22.51	23.60	34.03	35.10	32.25	25.54	19.90	19.59	23.79	22.43	15.61
Enterprise Value to NOPAT (EV/NOPAT)	24.98	26.78	23.42	24.94	22.65	19.83	21.10	19.98	22.52	20.61	23.59
Enterprise Value to Operating Cash Flow (EV/OCF)	18.80	21.32	19.98	22.83	19.67	16.33	16.61	14.92	16.07	14.89	16.45
Enterprise Value to Free Cash Flow (EV/FCFF)	24.01	23.03	118.03	1,280.64	31.87	21.89	11.93	15.10	40.53	39.65	130.11
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.43	0.52	0.75	0.60	0.42	0.43	0.48	0.58	0.51	0.51	0.67
Long-Term Debt to Equity	0.37	0.35	0.49	0.44	0.37	0.38	0.36	0.44	0.45	0.43	0.49
Financial Leverage	0.01	-0.01	0.16	0.11	0.03	0.02	0.20	0.22	0.15	0.13	0.14
Leverage Ratio	2.45	2.45	2.57	2.42	2.34	2.44	2.61	2.52	2.44	2.48	2.47
Compound Leverage Factor	2.49	2.53	2.60	2.46	2.42	2.55	2.77	2.58	2.51	2.57	2.49
Debt to Total Capital	30.04%	34.04%	42.74%	37.38%	29.58%	29.90%	32.45%	36.71%	33.76%	33.88%	40.08%
Short-Term Debt to Total Capital	4.15%	10.95%	14.53%	9.59%	3.83%	3.52%	8.25%	8.72%	4.21%	5.53%	10.66%
Long-Term Debt to Total Capital	25.89%	23.09%	28.22%	27.79%	25.76%	26.38%	24.20%	27.99%	29.54%	28.35%	29.42%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	1.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	69.96%	65.96%	57.26%	61.59%	70.42%	70.10%	67.55%	63.29%	66.24%	66.12%	59.92%
Debt to EBITDA	1.28	1.52	2.77	2.32	1.51	1.33	1.26	1.59	1.47	1.56	1.56
Net Debt to EBITDA	-0.08	0.66	1.08	0.87	0.32	0.29	0.28	0.61	0.64	0.52	0.40
Long-Term Debt to EBITDA	1.10	1.03	1.83	1.72	1.32	1.17	0.94	1.21	1.29	1.31	1.15
Debt to NOPAT	1.97	2.35	3.03	2.61	1.70	1.56	1.84	2.25	1.99	2.09	3.02
Net Debt to NOPAT	-0.13	1.03	1.18	0.98	0.36	0.34	0.41	0.87	0.86	0.69	0.78
Long-Term Debt to NOPAT	1.70	1.59	2.00	1.94	1.48	1.38	1.37	1.72	1.74	1.75	2.22
Altman Z-Score	4.13	3.78	3.15	3.65	4.40	4.16	4.10	3.73	3.94	3.74	4.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.82%	0.00%	0.00%	0.00%	0.85%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.43	0.99	1.07	1.12	1.21	1.16	1.17	1.07	1.03	1.11	1.26
Quick Ratio	1.10	0.65	0.68	0.84	0.86	0.82	0.84	0.77	0.70	0.78	0.96
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5,068	5,128	-10,032	-12,164	-520	1,830	19,213	11,068	-3,909	-5,261	-9,158
Operating Cash Flow to CapEx	665.68%	391.65%	395.75%	399.05%	885.22%	535.63%	612.56%	918.92%	816.45%	447.63%	808.91%
Free Cash Flow to Firm to Interest Expense	99.37	28.97	-47.32	-56.06	-2.71	12.12	123.95	40.99	-20.25	-38.40	-44.89
Operating Cash Flow to Interest Expense	123.22	30.23	15.36	19.27	39.01	52.07	23.59	20.86	41.41	50.97	20.46
Operating Cash Flow Less CapEx to Interest Expense	104.71	22.51	11.48	14.44	34.60	42.35	19.74	18.59	36.34	39.58	17.93
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.44	0.43	0.41	0.41	0.45	0.48	0.47	0.46	0.51	0.51	0.49
Accounts Receivable Turnover	5.01	5.46	4.85	4.55	4.97	5.89	5.47	5.32	5.66	5.98	5.77
Inventory Turnover	2.10	2.38	1.99	1.83	1.98	2.48	2.18	2.14	2.28	2.33	2.36
Fixed Asset Turnover	4.22	4.33	3.99	3.85	4.13	4.50	4.30	4.29	4.46	4.40	4.41
Accounts Payable Turnover	2.43	2.35	2.46	2.20	2.45	2.72	2.92	2.78	3.14	2.76	3.20
Days Sales Outstanding (DSO)	72.80	66.90	75.26	80.14	73.39	61.96	66.69	68.66	64.45	61.06	63.26
Days Inventory Outstanding (DIO)	173.62	153.26	183.38	199.72	184.20	147.42	167.38	170.73	160.04	156.95	154.95
Days Payable Outstanding (DPO)	150.42	155.40	148.08	165.92	149.05	134.17	125.11	131.44	116.39	132.49	114.20
Cash Conversion Cycle (CCC)	96.00	64.75	110.56	113.94	108.54	75.21	108.95	107.95	108.11	85.52	104.01
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	72,547	73,419	91,468	93,506	77,638	75,179	77,434	87,554	85,612	83,602	91,580
Invested Capital Turnover	1.06	1.07	0.92	0.88	1.02	1.15	1.01	0.96	1.07	1.12	1.06
Increase / (Decrease) in Invested Capital	-652	-2,747	13,999	17,120	5,091	1,760	-14,034	-5,952	7,974	8,423	14,146
Enterprise Value (EV)	405,711	451,852	409,079	435,442	398,784	372,143	385,168	367,776	403,983	361,338	407,622
Market Capitalization	407,763	434,491	388,480	417,085	392,374	365,738	377,754	351,760	388,529	349,226	394,151
Book Value per Share	$28.37	$29.38	$27.21	$28.92	$27.41	$28.57	$29.08	$29.72	$29.14	$29.69	$32.44
Tangible Book Value per Share	$0.33	$0.87	($8.51)	($6.36)	$0.03	($0.81)	($0.37)	($5.17)	($5.87)	($4.29)	($1.29)
Total Capital	106,626	116,446	123,776	122,011	101,149	98,106	103,652	113,029	105,909	108,124	130,361
Total Debt	32,027	39,642	52,907	45,602	29,921	29,332	33,632	41,491	35,751	36,634	52,252
Total Long-Term Debt	27,603	26,886	34,928	33,901	26,051	25,881	25,082	31,636	31,289	30,651	38,355
Net Debt	-2,052	17,361	20,599	17,097	6,410	6,405	7,414	16,016	15,454	12,112	13,471
Capital Expenditures (CapEx)	944	1,366	823	1,048	846	1,468	597	613	979	1,560	516
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9,962	-10,033	-10,314	-10,407	-10,308	-12,263	-9,391	-11,736	-14,345	-12,967	-10,236
Debt-free Net Working Capital (DFNWC)	24,117	12,248	21,994	18,098	13,203	10,664	16,827	13,739	5,952	11,555	28,545
Net Working Capital (NWC)	19,693	-508	4,015	6,397	9,333	7,213	8,277	3,884	1,490	5,572	14,648
Net Nonoperating Expense (NNE)	-42	-1,139	4,035	-188	-21,457	-459	1,924	430	1,371	-269	-6,011
Net Nonoperating Obligations (NNO)	-2,052	-3,385	20,599	17,097	6,410	6,405	7,414	16,016	15,454	12,112	13,471
Total Depreciation and Amortization (D&A)	1,685	1,772	1,880	1,934	1,829	1,843	1,815	1,782	1,846	1,896	1,772
Debt-free, Cash-free Net Working Capital to Revenue	-12.90%	-12.54%	-13.32%	-13.88%	-13.51%	-14.40%	-10.96%	-13.56%	-16.36%	-14.60%	-11.46%
Debt-free Net Working Capital to Revenue	31.24%	15.31%	28.39%	24.14%	17.30%	12.52%	19.65%	15.87%	6.79%	13.01%	31.95%
Net Working Capital to Revenue	25.51%	-0.64%	5.18%	8.53%	12.23%	8.47%	9.66%	4.49%	1.70%	6.27%	16.40%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.70	$1.34	($0.03)	$1.98	$10.32	$1.61	$1.35	$1.95	$1.12	$1.42	$4.57
Adjusted Weighted Average Basic Shares Outstanding	2.63B	2.63B	2.61B	2.60B	2.52B	2.53B	2.41B	2.41B	2.41B	2.41B	2.41B
Adjusted Diluted Earnings per Share	$1.68	$1.32	($0.03)	$1.96	$10.21	$1.58	$1.34	$1.93	$1.11	$1.41	$4.54
Adjusted Weighted Average Diluted Shares Outstanding	2.66B	2.66B	2.61B	2.63B	2.55B	2.56B	2.43B	2.42B	2.43B	2.43B	2.42B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.61B	2.60B	2.60B	2.60B	2.41B	2.41B	2.41B	2.41B	2.41B	2.41B	2.41B
Normalized Net Operating Profit after Tax (NOPAT)	4,470	2,427	4,058	5,079	4,701	3,638	5,322	5,106	4,098	3,199	5,002
Normalized NOPAT Margin	22.35%	19.34%	19.42%	23.60%	22.02%	17.00%	24.89%	22.75%	18.24%	14.20%	22.85%
Pre Tax Income Margin	25.87%	19.80%	-6.16%	29.30%	24.43%	22.56%	17.37%	25.61%	14.85%	17.26%	62.26%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	99.47	13.60	-6.00	28.56	26.22	30.56	22.61	20.83	16.78	27.32	66.19
NOPAT to Interest Expense	86.59	13.45	18.71	22.84	23.81	23.78	33.41	18.95	21.06	23.08	24.45
EBIT Less CapEx to Interest Expense	80.96	5.89	-9.89	23.73	21.82	20.83	18.76	18.56	11.71	15.93	63.66
NOPAT Less CapEx to Interest Expense	68.08	5.73	14.83	18.01	19.40	14.05	29.56	16.68	15.99	11.69	21.92
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	60.13%	65.11%	93.03%	91.60%	34.25%	33.48%	30.40%	30.49%	79.71%	84.05%	54.76%
Augmented Payout Ratio	89.94%	98.75%	155.86%	148.31%	52.04%	47.86%	38.18%	37.71%	95.82%	101.34%	68.90%

Frequently Asked Questions About Johnson & Johnson's Financials

When does Johnson & Johnson's financial year end?

According to the most recent income statement we have on file, Johnson & Johnson's fiscal year ends in December. Their fiscal year 2024 ended on December 29, 2024.

How has Johnson & Johnson's net income changed over the last 9 years?

Johnson & Johnson's net income appears to be on an upward trend, with a most recent value of $14.07 billion in 2024, falling from $15.41 billion in 2015. The previous period was $35.15 billion in 2023. Check out Johnson & Johnson's forecast to explore projected trends and price targets.

What is Johnson & Johnson's operating income?

Johnson & Johnson's total operating income in 2024 was $20.80 billion, based on the following breakdown:

Total Gross Profit: $61.35 billion
Total Operating Expenses: $40.55 billion

How has Johnson & Johnson revenue changed over the last 9 years?

Over the last 9 years, Johnson & Johnson's total revenue changed from $70.07 billion in 2015 to $88.82 billion in 2024, a change of 26.8%.

How much debt does Johnson & Johnson have?

Johnson & Johnson's total liabilities were at $108.61 billion at the end of 2024, a 10.0% increase from 2023, and a 74.4% increase since 2015.

How much cash does Johnson & Johnson have?

In the past 9 years, Johnson & Johnson's cash and equivalents has ranged from $12.89 billion in 2022 to $24.11 billion in 2024, and is currently $24.11 billion as of their latest financial filing in 2024.

How has Johnson & Johnson's book value per share changed over the last 9 years?

Over the last 9 years, Johnson & Johnson's book value per share changed from 25.71 in 2015 to 29.69 in 2024, a change of 15.5%.

Related Companies

This page (NYSE:JNJ) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Financials

Frequently Asked Questions About Johnson & Johnson's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Johnson & Johnson (JNJ) Financials

Annual Income Statements for Johnson & Johnson

Quarterly Income Statements for Johnson & Johnson

Annual Cash Flow Statements for Johnson & Johnson

Quarterly Cash Flow Statements for Johnson & Johnson

Annual Balance Sheets for Johnson & Johnson

Quarterly Balance Sheets for Johnson & Johnson

Annual Metrics and Ratios for Johnson & Johnson

Quarterly Metrics and Ratios for Johnson & Johnson

Frequently Asked Questions About Johnson & Johnson's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools